BT BlossomHill Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Source id SEC:blossomhill-therapeutics-inc-48a98e US · SEC (Form 4) Mcap US$568.8M Track the BlossomHill Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €568.8m. The latest transaction was disclosed on 12 August 2026 (Acquisition). Among the most active insiders: ORBIMED ADVISORS LLC. All data is free.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 August 2026
All Executives21 Thresholds0 Prospectus0 Other0
Declarations 21 total
▲ Director · Executives · 10 Aug 2026
625,000 shares @ US$16.00 100.0% of flow Common Stock SEC:0000947871-26-000784:2
Canonical exit: 8 Nov 2026 (T+90) ▲ Director · Executives · 10 Aug 2026
625,000 shares @ US$16.00 100.0% of flow Common Stock SEC:0000947871-26-000785:2
Canonical exit: 8 Nov 2026 (T+90) ● Director · Executives · 10 Aug 2026
1,039,996 shares Common Stock SEC:0000947871-26-000784:0
● Director · Executives · 10 Aug 2026
1,049,283 shares Common Stock SEC:0000947871-26-000784:1
● Director · Executives · 10 Aug 2026
1,039,996 shares Common Stock SEC:0000947871-26-000785:0
● Director · Executives · 10 Aug 2026
1,049,283 shares Common Stock SEC:0000947871-26-000785:1
▲ Director · Executives · 10 Aug 2026
312,500 shares @ US$16.00 100.0% of flow Common Stock SEC:0001231919-26-000852:2
Canonical exit: 8 Nov 2026 (T+90) ▲ Director · Executives · 10 Aug 2026
6,000 shares @ US$16.00 100.0% of flow Common Stock SEC:0001478916-26-000015:0
Canonical exit: 8 Nov 2026 (T+90) ▲ Chief Financial Officer · Executives · 10 Aug 2026
700 shares @ US$16.00 100.0% of flow Common Stock SEC:0001678152-26-000003:0
Canonical exit: 8 Nov 2026 (T+90) ▲ General Counsel · Executives · 7 Aug 2026
2,500 shares @ US$15.80 52.9% of flow Common Stock SEC:0002143905-26-000003:0
Canonical exit: 5 Nov 2026 (T+90) ▲ General Counsel · Executives · 10 Aug 2026
2,200 shares @ US$16.00 47.1% of flow Common Stock SEC:0002143905-26-000003:1
Canonical exit: 8 Nov 2026 (T+90) ● Director · Executives · 10 Aug 2026
578,524 shares Common Stock SEC:0001840599-26-000003:0
● Director · Executives · 10 Aug 2026
1,599,993 shares Common Stock SEC:0001231919-26-000852:0
● Director · Executives · 10 Aug 2026
1,701,541 shares Common Stock SEC:0001231919-26-000852:1
● Executive Chairman · Executives · 10 Aug 2026
1,600,682 shares Common Stock SEC:0001772233-26-000005:0
● General Counsel · Executives · 10 Aug 2026
22,687 shares Common Stock SEC:0002143905-26-000003:2
● Executive Chairman · Executives · 10 Aug 2026
113,435 shares Common Stock SEC:0001772233-26-000005:1
● Executive Chairman · Executives · 10 Aug 2026
124,779 shares Common Stock SEC:0001772233-26-000005:2
● President and CEO · Executives · 10 Aug 2026
1,600,682 shares Common Stock SEC:0001772259-26-000005:0
● President and CEO · Executives · 10 Aug 2026
113,435 shares Common Stock SEC:0001772259-26-000005:1
● President and CEO · Executives · 10 Aug 2026
124,779 shares Common Stock SEC:0001772259-26-000005:2
About BlossomHill Therapeutics, Inc. BlossomHill Therapeutics, Inc. is a company focused on developing innovative treatments for chronic diseases. It is listed on the XNAS market.